SecBot SecBot
8-K ·Filed Mar 5, 2026

IVVD

Invivyd, Inc.
BULLISH
Impact 8/10
Horizonmonths Processed8mo ago SEC0001193125-26-092528
8-K Item 2.02: Earnings release
Actionable Insight ▲ Bullish

The strong revenue growth, substantial cash position, and positive clinical trial progress for VYD2311 create a favorable outlook. Traders should monitor the mid-2026 top-line data readout from the DECLARATION trial as a key catalyst, which could significantly impact the stock if results are positive.

DirectionBullish
Confidencehigh
Horizonmonths

How the stock moved after the report

⚠ Clustered BULLISH VIEWSTOCK BELOW ENTRY AT T+60
Entry
$1.74
T+0 close · Mar 5, 2026 · via day close
Latest settled
−29.89%
T+60 · $1.22
Vs SPY
−41.19%
α at T+60
Horizons
All settled
through T+60
  1. T+0 · Mar 5 $1.74entry
  2. T+1 · 9mo ago +3.45%α +4.76% · $1.80
  3. T+5 · 8mo ago +3.45%α +5.69% · $1.80
  4. T+20 · 8mo ago −26.44%α −22.65% · $1.28
  5. T+60 · 6mo ago −29.89%α −41.19% · $1.22
Loading chart...

How similar events traded

How similar events traded

See how far stocks moved after events like this one.

Subscribe for Full Access

Executive Summary

Invivyd reported strong financial and clinical progress, with Q4 2025 PEMGARDA net product revenue of $17.2 million (25% YoY growth) and a year-end cash position of $226.7 million after raising over $200 million in 2H 2025. The company's pivotal DECLARATION Phase 3 trial for its COVID-19 antibody VYD2311 is fully enrolled with top-line data expected mid-2026, and the FDA granted Fast Track designation for the candidate.

Key Financial Metrics

Revenue
$53.4M
+110.5% YoY
EPS
$-0.30

Key Facts

  • Achieved Q4 2025 PEMGARDA net product revenue of $17.2 million, representing 25% growth year-over-year and 31% growth quarter-over-quarter
  • 2025 year-end cash and cash equivalents of $226.7 million after raising over $200 million from financing transactions in 2H 2025
  • Announced initiation of DECLARATION Phase 3 pivotal clinical trial of vaccine-alternative antibody VYD2311 to prevent COVID, with top-line data expected mid-2026
  • Fast Track designation for VYD2311 granted by FDA in December 2025
  • DECLARATION trial on track with full enrollment achieved
  • Distinguished scientist and physician Michael Mina, M.D., Ph.D., appointed Chief Medical Officer

Financial Impact

Q4 2025 revenue of $17.2 million (25% YoY growth) and full-year 2025 revenue of $53.4 million (111% YoY growth)

revenuecash

Segment Breakdown

SegmentRevenueGrowth
PEMGARDA$53.4M+110.5%

Risk Factors

  • Clinical trial results may not meet expectations
  • Regulatory approval is not guaranteed even with Fast Track designation
  • Future revenue depends on successful commercialization of pipeline products

Market Snapshot

Exchange
Nasdaq

Investment Themes

Documents Analyzed

This report is based on 6 SEC documents filed with EDGAR.

DocumentAccession Number
8-K Filing (Primary)0001193125-26-092528
Document: d118119d8k.htm0001193125-26-092528
Document: d118119dex992.htm0001193125-26-092528
Document: 0001193125-26-092528-index-headers.html0001193125-26-092528
Document: 0001193125-26-092528-index.html0001193125-26-092528
Document: 0001193125-26-092528.txt0001193125-26-092528

Track record

19 reports on IVVD

Performance horizon

2 of 4 bullish or bearish reports moved the stock their way by T+5. Best: +35.85% at T+20 after the Jul 6, 2026 report. 3 of 4 went positive at some point.

Filters
  1. Nov 16, 2026today Press Release Neutral 6/10 Entry $0.5603 Now $0.5380 −3.98% settles Nov 23
  2. Nov 3, 202613d ago Press Release Neutral 2/10 Entry $0.5815 to $0.5744 Now $0.5380 −7.48% ▼ −1.22% −0.63% vs SPY
  3. Sep 29, 20266w ago 8-K Bullish 7/10 Entry $0.8501 to $0.8064 Now $0.5380 −36.71% ▼ −5.14% −7.09% vs SPY
  4. Sep 22, 20267w ago Institutional Cluster Mixed 3/10 Entry $0.9640 to $0.8501 Now $0.5380 −44.19% ▼ −11.82% −10.63% vs SPY
  5. Sep 1, 202610w ago 8-K Neutral 6/10 Entry $0.8800 to $0.7973 Now $0.5380 −38.86% ▼ −9.40% −9.48% vs SPY
  6. Aug 17, 202613w ago 144 Neutral 2/10 Entry $0.8680 to $0.9387 Now $0.5380 −38.02% ▲ +8.15% +8.35% vs SPY
  7. Jul 6, 202619w ago 8-K Bearish 6/10 Entry $0.8340 to $0.7834 Now $0.5380 +35.49% ▲ +6.07% +6.56% vs SPY
  8. Jun 16, 202621w ago Press Release Neutral 5/10 Entry $0.8918 to $0.9346 Now $0.5380 −39.67% ▲ +4.80% +7.03% vs SPY
  9. Jun 11, 202622w ago Institutional Cluster Mixed 4/10 Entry $0.8125 to $0.9312 Now $0.5380 −33.78% ▲ +14.61% +14.18% vs SPY
  10. Jun 9, 202622w ago Press Release Neutral 4/10 Entry $0.9900 to $0.8686 Now $0.5380 −45.66% ▼ −12.26% −14.67% vs SPY
Showing 10 of 19

US Market Status

Market Closed · Opens in 6h 14m

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers
Report published Mar 5, 2026